PPA
PRLD icon

Parametric Portfolio Associates’s Prelude Therapeutics PRLD Stock Holding History

Parametric Portfolio Associates’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10,130
Closed -$317K – 3679
2021
Q3 		$317K Buy
+10,130
New +$328K ﹤0.01% 3279
2021
Q2 		– Sell
-5,178
Closed -$224K – 3591
2021
Q1 		$224K Buy
+5,178
New +$344K ﹤0.01% 3835

Other funds holding PRLD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Parametric Portfolio Associates's PRLD Position: Q4 2021 in Review

Parametric Portfolio Associates sold out of Prelude Therapeutics (PRLD) in Q4 2021, closing a stake of 10,130 shares — an estimated $317K sold.

Parametric Portfolio Associates first reported a position in PRLD in Q1 2021 and held it in 2 quarters. The position peaked at $317K in Q3 2021. 75 funds tracked by Wall St. Rank hold PRLD as of Q4 2021.

  • Parametric Portfolio Associates reported no remaining Prelude Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Parametric Portfolio Associates sold 10,130 Prelude Therapeutics shares in Q4 2021, an estimated $317K.
  • Parametric Portfolio Associates first reported a position in Prelude Therapeutics in Q1 2021 and held it in 2 quarters.
  • Parametric Portfolio Associates's Prelude Therapeutics position peaked at $317K in Q3 2021.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q4 2021.

Based on Parametric Portfolio Associates's 13F filing for Q4 2021, filed 15 Feb 2022.